MedTrace Logo

Treatment of SARS-CoV-2 Virus Disease (COVID-19) in Humans With Hemopurifier® Device

NCT04595903 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2022-12-20

No results posted yet for this study

Summary

This is an Early Feasibility Study (EFS) investigating the use of the Hemopurifier® in the treatment of SARS-CoV-2 Virus Disease (COVID-19).

Conditions

Interventions

DEVICE

Hemopurifier

Hemopurifier treatments will be one four to six hour treatment session daily for up to 4 days

Sponsors & Collaborators

  • Aethlon Medical Inc.

    lead INDUSTRY

Principal Investigators

  • Steven LaRosa, MD · Aethlon Medical Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2022-11-14
Completion
2022-11-14
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04595903 on ClinicalTrials.gov